E i i 1 E i # [ I i ■ l r l = ri i - r l = = t F l l 1 i i i = iQoncept TG Therapeutics (NASDAQ:TGTX) beat Q2 Street consensus estimates and my $67-69 million estimate range by reporting Briumvi net sales of $72.6 million and total revenues of $73.5 million. The company also achieved positive cash flow one quarter ahead of my expectations, the full-year guidance range was raised by $15 million at the mid-point, and the company secured a new $250 million credit facility to retire the existing facility with H ...